XML 20 R10.htm IDEA: XBRL DOCUMENT
v3.19.2

Inventories | 6 Months Ended
--- | ---
Jun. 30, 2019
Inventories |
Inventories | 4.Inventories ​ Inventories are comprised of unprocessed tissue, work-in-process, Avance® Nerve Graft, Axoguard® Nerve Connector, Axoguard Nerve Protector, Avive® Soft Tissue Membrane, AcroVal Neurosensory and Motor Testing System, Axotouch® Two-Point Discriminator and supplies and are valued at the lower of cost (first-in, first-out) or net realizable value and consist of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | December 31, |
​ | ​ | 2019 | ​ | 2018 | ​
​ | ​ | ​ | ​ | ​ | ​
Finished goods | ​ | $ | 10,367 | ​ | $ | 9,194 | ​
Work in process | ​ |  | 558 | ​ |  | 454 | ​
Raw materials | ​ | ​ | 2,662 | ​ |  | 2,334 | ​
Inventories | ​ | $ | 13,587 | ​ | $ | 11,982 | ​
​ For the six months ended June 30, 2019 and 2018, the Company had adjustments to the provision for inventory write downs of ($95) and $582 respectively.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration